July 7, 2025

Higher Medicine (HMd) and its Delaware subsidiary, HigherTherapeutics (HTx), announced it has been awarded a grant in the Spring 2025 EDGE competition by the Delaware Division of Small Business.

The EDGE (Encouraging Development, Growth and Expansion) Grant is a competitive program that supports early-stage Delaware businesses poised for scalable impact. Each round, five STEM-based companies are selected to receive up to $100,000 in funding. HMd/HTx was one of just five STEM awardees chosen statewide.

The EDGE funding will support IND-enabling regulatory research as well as early team building. The investment will help advance lead compound validation, strengthen internal capabilities, and prepare the company for future partnerships and clinical execution.

“I am incredibly excited by the diverse range of small businesses that we were able to support during this round of the EDGE competition,” said CJ Bell, Director of the Delaware Division of Small Business. “These companies are contributing to the quality of life of Delawareans in a variety of ways. I’m proud that through this funding, we are able to help elevate them to the next level.”

The award was the result of a competitive review and live pitch process, in which finalists were selected from a pool of 139 applicants across STEM and non-STEM categories.

To learn more about the EDGE Grant and view the full list of Spring 2025 recipients, visit:

https://business.delaware.gov/edge

https://delawarebusinesstimes.com/news-briefs/delaware-division-of-small-business-award-ten-small-businesses-edge-grants/

Latest News

Our platform offers a variety of resources to keep you informed about our latest programs, key updates, achievements, and other significant developments in the field of healthcare and medicine.

Company Announcements
July 1, 2025

Higher Medicine Establishes Higher Therapeutics to Advance Friedreich’s Ataxia Program

Higher Medicine announces the formation of Higher Therapeutics, a wholly-owned, Delaware-based subsidiary dedicated to developing novel treatments for Friedreich’s ataxia.

Company Announcements
June 16, 2025

Higher Medicine Announces a Pre-Seed Builder Fund Investment from TEDCO

TEDCO's Pre-Seed Builder Fund, one of the state's marquee investment vehicles in Maryland, invested in Higher Medicine.

Company Announcements
June 12, 2025

Higher Medicine Announces Strategic Investment and Clinical Alliance with 5 Horizons Capital to Advance a Clinical Trial

Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.

Company Announcements
June 2, 2025

Higher Medicine Joins BIO 2025 in Boston as a part of the Maryland Delegation

Higher Medicine attends the 2025 BIO International Convention from June 16–19 in Boston, MA, as part of the official Maryland delegation.

Company Announcements
June 2, 2025

Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology

Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.

Company Announcements
April 25, 2025

Higher Medicine Selected for the Maryland TEDCO SBIR/STTR Proposal Lab 2025 Cohort

Funded by TEDCO and administered by the leading experts in the field, Proposal Lab supports companies in securing competitive and prestigious NSF and other grants to advance their R&D portfolios.